Atorvastatin v placebo in patients with type 2 diabetes mellitus at median 3.9 years†
| Outcomes | Atorvastatin | Placebo | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| †Composite endpoint = an acute coronary heart disease event, coronary revascularisation, or stroke. Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | ||||
| Composite endpoint | 5.8% | 9.0% | 35% (16 to 51) | 32 (20 to 79) |
| Acute coronary events | 3.6% | 5.5% | 35% (8 to 54) | 53 (29 to 273) |
| Stroke | 1.5% | 2.8% | 47% (11 to 68) | 78 (42 to 411) |
| Coronary revascularisaiton | 1.7% | 2.4% | 30% (−16 to 58) | Not significant |